Trending...
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- Foresight Practitioner Conference 2025 – Dates, Venue, Speakers, And Competition Finalists Announced
Working With World-Class Institutions/Collaborators to Provide Novel Treatment Approaches. Stock Symbol: GNPX
AUSTIN, Texas - nvtip -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on nvtip.com
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on nvtip.com
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on nvtip.com
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- Morphy's Heads to Las Vegas Jan. 24-25 to Host Old West Show & Auction Featuring Cowboy, Western and Native American Art and Antiques
- "Global Accreditation Failures: How the Wuhan Lab Certification Exposed Systemic Weaknesses and Paved the Way for COVID-19"
- TradeTek 2.0 Construction Takeoff and Estimating Software
- Get to know Dr. Raphael E. Cuomo, PhD, Professor and Scientist at the University of California, San Diego
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on nvtip.com
- Platinum-Level Comfortable Lumbar Support & Seat Cushion Set Available On Major Online Stores
- Ohio Medicare (Plan Brian C. Moore), has once again been distinguished as Ohio's Top-Ranked and Number-One-Rated "Best Choice" Medicare Expert!
- Manchester Insurance Announces Best Rates in Florida for Home Insurance
- New Middle East Partnership for up to $40 Million Supporting Entry Into Emerging Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- King Dumpsters Canton Launches Affordable, Reliable Dumpster Rental Services in Canton, Ohio
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on nvtip.com
- IntellaTriage Launches New Patient Engagement Service
- Cascadia Global Security Launches Cascadia Off-Duty
- Anti-Racism Song from Neal Fox Drops in Time for Martin Luther King Day
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- Orcas Island Property Owner Returns Two Prime Waterfront Properties to the Market
- Muench Workshops Welcomes New Partners Luke Dray and Sara Linssen, Announces Retirement of Andy Williams
- NuNorm Announces Stop Soldier Suicide as This Year's EQUAL Grant Recipient
- Ride Into the Future - OKAI Celebrates Innovation at CES 2025 by Revolutionizing Electric Mobility with Next-Gen Successors
- Darrin Jones: The Creative Force Behind the Trends—Raising Questions About Influence in The Weeknd's Music
- Foresight Practitioner Conference 2025 – Dates, Venue, Speakers, And Competition Finalists Announced
- AC Future's AI Transformer Home Shines at CES 2025, Winning Multiple Tech Awards; Company Opens Customer Reservations
- ArcherMind Technology and Arraymo Unveil AI+OS Integration at CES 2025, Pioneering a New Era of Digital Intelligence
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- Best Plant Varieties for Windbreaks and Shelterbelts
- ROMOSS Showcases Latest Charging Innovations at CES 2025, Paving the Way for Global Market Expansion